Antiapoptotic B-cell lymphoma 2 (Bcl-2) targets the inositol 1,4,5-trisphosphate receptor (IP 3 R) via its BH4 domain, thereby suppressing IP 3 R Ca 2 þ -flux properties and protecting against Ca 2 þ -dependent apoptosis. Here, we directly compared IP 3 R inhibition by BH4-Bcl-2 and BH4-Bcl-Xl. In contrast to BH4-Bcl-2, BH4-Bcl-Xl neither bound the modulatory domain of IP 3 R nor inhibited IP 3 -induced Ca 2 þ release (IICR) in permeabilized and intact cells. We identified a critical residue in BH4-Bcl-2 (Lys17) not conserved in BH4-Bcl-Xl (Asp11). Changing Lys17 into Asp in BH4-Bcl-2 completely abolished its IP 3 R-binding and -inhibitory properties, whereas changing Asp11 into Lys in BH4-Bcl-Xl induced IP 3 R binding and inhibition. This difference in IP 3 R regulation between BH4-Bcl-2 and BH4-Bcl-Xl controls their antiapoptotic action. Although both BH4-Bcl-2 and BH4-Bcl-Xl had antiapoptotic activity, BH4-Bcl-2 was more potent than BH4-Bcl-Xl. The effect of BH4-Bcl-2, but not of BH4-Bcl-Xl, depended on its binding to IP 3 Rs. In agreement with the IP 3 R-binding properties, the antiapoptotic activity of BH4-Bcl-2 and BH4-Bcl-Xl was modulated by the Lys/Asp substitutions. Changing Lys17 into Asp in full-length Bcl-2 significantly decreased its binding to the IP 3 R, its ability to inhibit IICR and its protection against apoptotic stimuli. A single amino-acid difference between BH4-Bcl-2 and BH4-Bcl-Xl therefore underlies differential regulation of IP 3 Rs and Ca 2 þ -driven apoptosis by these functional domains. Mutating this residue affects the function of Bcl-2 in Ca 2 þ signaling and apoptosis. Pro-and anti-apoptotic B-cell lymphoma 2 (Bcl-2) family members control cell survival by regulating programmed cell death and autophagy.
Pro-and anti-apoptotic B-cell lymphoma 2 (Bcl-2) family members control cell survival by regulating programmed cell death and autophagy. 1 The founding member is Bcl-2, a 26-kDa protein localized in the mitochondrial and endoplasmicreticulum (ER) membranes. Members of this protein family are characterized by the presence of Bcl-2 homology domains (BH domains). 2, 3 Although multidomain proapoptotic proteins contain three BH domains (BH1, BH2 and BH3), the antiapoptotic proteins, like Bcl-2 and Bcl-Xl, are characterized by an additional BH domain (BH4). 1 The BH1, BH3 and BH2 domains of the antiapoptotic Bcl-2 family proteins form a hydrophobic pocket that binds the BH3 domain of proapoptotic proteins, thereby counteracting their proapoptotic activity. 4 Besides this hydrophobic cleft, the BH4 domain is also essential for the antiapoptotic activity of Bcl-2. 5, 6 Moreover, Ca 2 þ signaling from the ER to the mitochondria plays an important role in apoptosis initiation. 7 Several pro-and anti-apoptotic Bcl-2 proteins localize at the ER membrane, where they modulate Ca 2 þ -release events 8, 9 (recently reviewed in Rong et al. 10 and Rizzuto et al. 11 ). Bcl-2 proteins thereby influence mitochondrial function because of the close proximity of ER and mitochondrial membranes. [12] [13] [14] Ca 2 þ transfer via the ER-mitochondria connection plays a bimodal role in cell survival. 15, 16 [20] [21] [22] [23] [24] [25] However, the localization of their interaction sites on the IP 3 R as well as the physiological roles of these interactions remain unsolved. Different, not mutually exclusive, mechanisms have been proposed. (1) Increasing the ratio of anti-over pro-apoptotic Bcl-2 proteins caused IP 3 R sensitization, enhancing basal IP 3 R-mediated Ca 2 þ leak and reducing steady-state [Ca 2 þ ] in the ER. 20 (2) Bcl-Xl interacted with the C-terminus of IP 3 Rs, promoting spontaneous Ca 2 þ oscillations and enhancing mitochondrial bioenergetics. 23, 26 (3) Bcl-2 directly inhibited IP 3 Rs without altering steady-state ER Ca 2 þ levels. 21, 22, 27 Recently, the Bcl-2 interaction domain was identified in the central, modulatory region of the IP 3 R (amino acids (a.a.) 1389-1408). 28 Disturbing endogenous IP 3 R/Bcl-2 complexes potentiated IP 3 -induced Ca 2 þ release (IICR) and sensitized cells toward proapoptotic Ca 2 þ signaling. 28 The BH4 domain of Bcl-2 was necessary and sufficient for interaction with the IP 3 R. 29, 30 (4) Bcl-Xl reduced the expression levels of IP 3 Rs via a decreased binding of NFATc2 (nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 2) to the IP 3 R promoter, 31 thereby reducing IICR. Here, we directly compared the regulation of IP 3 Rs by the BH4 domains of Bcl-2 and Bcl-Xl. Our results indicate that although the BH4 domain of Bcl-2 and Bcl-Xl are very similar in sequence and structure, a difference in one single residue between BH4-Bcl-2 and BH4-Bcl-Xl critically determined its IP 3 R binding, suppression of IP 3 R activity and protection against IP 3 R-driven apoptosis.
Results BH4-Bcl-2 and BH4-Bcl-Xl differentially regulate IICR. The structure of antiapoptotic Bcl-2 and of a monomeric subunit of the IP 3 R1 is depicted in Figure 1a , including the interaction of Bcl-2 via its BH4 domain with the IP 3 R1. The IP 3 R-derived peptide (IDP; a.a. 1389-1408) corresponds to the Bcl-2-binding site on IP 3 R1 and is therefore able to disrupt Bcl-2/IP 3 R interaction in a competitive way. IDP completely alleviates the inhibitory action of the BH4 domain of Bcl-2 on IP 3 Rs without affecting other BH4-domain targets, like voltage-dependent anion channel (VDAC) and calcineurin. 29 Thus, IDP is an excellent tool to decipher the role of IP 3 R in the observed actions of BH4-Bcl-2 on intracellular Ca 2 þ signaling and cell death. Here, we directly compared the effect of BH4-Bcl-2 and BH4-Bcl-Xl on IICR using a unidirectional 45 Ca 2 þ -flux assay in saponin-permeabilized mouse embryonic fibroblasts (MEF cells) in which the non-mitochondrial Ca 2 þ stores were loaded to steady state with 45 Ca 2 þ . After adding 4 mM thapsigargin (TG), the efflux of 45 Ca 2 þ was followed in the presence of 1 mM ethylene glycol tetraacetic acid (EGTA). This assay allows the quantitative assessment of Ca 2 þ -efflux properties under unidirectional conditions in the absence of ER and mitochondrial Ca 2 þ -uptake activity. Ca 2 þ content ( Figure 1b ) and fractional loss ( Figure 1c ) were plotted as a function of time. Figure 1b shows that because of an inherent Ca 2 þ leak, the Ca 2 þ content of the stores slowly decreased over time, whereas adding IP 3 (3 mM) accelerated the decrease in Ca 2 þ content due to IICR, observed as a steep increase in the fractional loss ( Figure 1c ). The BH4 domains of Bcl-2 (BH4-Bcl-2; a.a. and Bcl-Xl (BH4-Bcl-Xl; a.a. 1-24) were produced as synthetic peptides. A scrambled version of the BH4 domain of Bcl-2 (BH4-Bcl-2SCR) and a 'binding-deficient' version of BH4-Bcl-2, in which the surface-accessible residues were altered (BH4-Bcl-2BIND), 30 were used as negative controls. The 45 Ca 2 þ -flux assays showed that BH4-Bcl-2 caused a potent concentration-dependent inhibition of IICR (Figures 1b and c) . Importantly, BH4-Bcl-2 did not alter the Ca 2 þ -leak rate from the ER in the absence of IP 3 . In contrast to BH4-Bcl-2, BH4-Bcl-2BIND and BH4-Bcl-2SCR did not inhibit IICR (Figure 1d and Supplementary Figures 1A and B) . BH4-Bcl-2 inhibited IICR with a half-maximal inhibitory concentration (IC 50 ) of B30 mM and an IC 100 of B100 mM (Figure 1d ). Strikingly, BH4-Bcl-Xl did not inhibit IICR (estimated IC 50 4500 mM) Figure 1 Although the BH4 domains of Bcl-2 and Bcl-Xl are similar in sequence and structure, they differentially regulate IP 3 R-mediated Ca 2 þ flux in permeabilized and intact cells. (a) Schematic presentation of the antiapoptotic Bcl-2-family members and the IP 3 R. The N-terminal BH4 domain is unique for antiapoptotic members. The secondary structure and primary sequence of BH4-Bcl-2 and BH4-Bcl-Xl are very similar. The cylindrical tube represents the predicted a-helical structure (PSIPREDv2. 3 incubation minus the fractional loss before the IP 3 addition. IICR in the presence of vehicle was set as 100% and other values were normalized to this value. A dose-response curve is shown for BH4-Bcl-2, a non-binding mutant of BH4-Bcl-2 (BH4-Bcl-2BIND), BH4-Bcl-2 SCR and BH4-Bcl-Xl, obtained from three to four independent experiments. Data points represent mean ± S.E.M. (e) Intracellular Ca 2 þ signals in intact C6 glioma cells were monitored using Fluo-3. Cells were loaded with caged IP 3 (50 mM) and electroporated with different BH4-domain peptides (20 mM) and/or IDP. IP 3 was released by a UV flash and a rapid increase in cytosolic [Ca 2 þ ] was observed. (f) Quantitative analysis of the area under the curve in (e) was obtained from at least six independent experiments and data are plotted as mean ± S.E.M. These data indicate that BH4-Bcl-2 significantly inhibited IICR, whereas the other BH4-domain peptides did not. IDP (20 mM) Figure  2C ) and 1 mM Mg-ATP (Supplementary Figure 2D) , and found that 40 mM BH4-Bcl-2 equally inhibited IICR.
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Next, we examined the differential regulation of IP 3 Rs by BH4-Bcl-2 and BH4-Bcl-Xl in C6 glioma cells, a cellular model optimized for in situ electroporation of membrane-impermeable molecules.
32,33
We loaded BH4-Bcl-2 or BH4-Bcl-Xl (both 20 mM) by electroporation and found that BH4-Bcl-2 inhibited IICR triggered by IP 3 photoliberation from its caged precursor in intact C6 cells (50 mM; Figures 1e and f), whereas BH4-Bcl-Xl did not. BH4-Bcl-2SCR and BH4-Bcl-2BIND control peptides did not reduce IICR. The inhibition by BH4-Bcl-2 was completely prevented by loading the cells with IDP (20 mM), indicating a competitive binding of BH4-Bcl-2 to IP 3 Rs. Similar results were obtained using adenosine 5 0 -triphosphate (ATP; 1 mM), a physiological agonist provoking IP 3 R-mediated Ca 2 þ release in these cells (Figures 1g and h ). Finally, we assessed the TG (2.5 mM)-releasable Ca 2 þ in these cells 1 min after exposing the cells to EGTA (1 mM) and found no differences among the different conditions (Figures 1i and j) . Hence, the decreased ATP-induced Ca 2 þ release in the presence of BH4-Bcl-2 was not because of decreased ER Ca 2 þ -store content.
These results indicate that BH4-Bcl-2 and BH4-Bcl-Xl differentially regulate IP 3 R function independently of the ER Ca 2 þ -store content. . Using GST pull-down assays, we found that BH4-Bcl-2, but not BH4-Bcl-Xl, strongly and specifically interacted with GST-Dom3. However, we consistently noticed a higher nonspecific binding of BH4-Bcl-Xl to GST than for BH4-Bcl-2. The reason for this is unclear. BH4-Bcl-2BIND was not pulled down by GST-Dom3 (Figures 2a and b) , indicating that surface-accessible residues are important for interaction with IP 3 Rs. We also assessed the binding of GST-Dom3 to BH4-Bcl-2 and BH4-Bcl-Xl in a more quantitative manner using surface plasmon resonance (SPR). We monitored the binding of GSTDom3 (Figures 3a-c) and GST (Supplementary Figures 3A-C and Figure 3e ) to the streptavidin-coated sensor chip containing immobilized biotinylated peptides. Background signals obtained from the reference flow cell containing the scrambled peptides were subtracted to generate response curves. In each sensorgram, the association phase is plotted. GST (up to 40 mM) bound to neither biotin-BH4-Bcl-2 nor biotin-BH4-Bcl-Xl (Supplementary Figures 3A-C) . GST-Dom3 displayed a concentration-dependent increase in resonance units, in the biotin-BH4-Bcl-2-containing flow cell (Figure 3a ). This indicates a specific binding toward biotin-BH4-Bcl-2 with estimated dissociation constant (K d ) of B1 mM (Figure 3c ). In the biotin-BH4-Bcl-Xl-containing flow cell (Figure 3b ), GST-Dom3 resulted in significantly less increase in resonance units (Figure 3c ).
We also monitored the binding of GST-Dom3 to biotin-BH4-Bcl-2BIND corrected for the response to the scrambled counterpart (Figure 3d ). Clearly, GST-Dom3 did not specifically bind to biotin-BH4-Bcl-2BIND. The negative values in the sensorgrams indicate a slightly higher binding of GST-Dom3 to the scrambled version.
As the Bcl-2-binding site 28 is largely conserved among the different IP 3 R isoforms, we compared the BH4-Bcl-2-binding properties of the GST-Dom3 (3.3 mM) derived from IP 3 R1, IP 3 R2 and IP 3 R3 (Figures 3e and f) . GST-Dom3 from all three IP 3 R isoforms bound to biotin-BH4-Bcl-2 with roughly similar potencies (Figures 3e and f) . The quality of the purified GST-fusion proteins was controlled using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; Figure 3g ). Identification of residues in BH4-Bcl-2 responsible for inhibiting IP 3 Rs. Next, we investigated which residues in BH4-Bcl-2 are responsible for interaction with IP 3 Rs. Based on a bioinformatics approach, 30 we successively changed the various predicted surface-accessible residues into alanines ( Figure 4a ) and investigated their properties toward inhibiting IICR as described in Figure 1 . We applied 60 mM of the different BH4-Bcl-2 mutant peptides. This concentration, when used for wild-type BH4-Bcl-2, reduced the IICR to B20% of its control value (Figure 4b ). This analysis revealed that BH4-Bcl-2 acts as a discontinuous binding domain, in which every surface-accessible residue (Asp10, Arg12, Lys17, His20, Tyr21, Gln25, Arg26, Tyr28) contributed to the inhibition of IICR. In particular, Lys17, His20, Tyr21 or Arg26 seemed critical for the inhibitory properties of BH4-Bcl-2. Moreover, changing these residues into an Ala may indirectly affect the binding of BH4-Bcl-2 to IP 3 Rs by altering its a-helical properties. It has to be noted that although minor changes in the secondary structure can occur, all Ala mutants displayed similar predicted a-helical properties as the wild-type BH4-Bcl-2 using PSIPRED vs3.0 (Supplementary Figure 4 , http://bioinf.cs.ucl.ac.uk/psipred/).
Sequence alignment identifies a difference of one critical residue essential for differential IP 3 R-inhibitory properties of BH4-Bcl-2 and BH4-Bcl-Xl. Sequence alignment shows that Lys17 (K17) in BH4-Bcl-2 corresponds to Asp11 (D11) in BH4-Bcl-Xl (Figure 5a ), thereby introducing a charge change in the middle of the a-helical structure. 29, 34, 35 Hence, we made a mutant BH4-Bcl-2 peptide in which we replaced Lys17 by an aspartate (BH4-Bcl-2 K/D) and a mutant BH4-Bcl-Xl peptide in which we replaced Asp11 by a lysine (BH4-Bcl-Xl D/K). Strikingly, we found that BH4-Bcl-2 K/D failed to inhibit IICR, whereas BH4-Bcl-Xl D/K strongly reduced IICR (Figures 5b and c) . Dose-response curves (Figure 5d ) indicated that BH4-Bcl-2 and BH4-Bcl-Xl D/K inhibited IICR with an IC 50 of 30 and 60 mM, respectively. In contrast, BH4-Bcl-Xl and BH4-Bcl-2 K/D were largely ineffective. The effects of the BH4-domain mutants on IICR were also observed in intact C6 glioma cells using caged IP 3 (Figures 5e and f) . In contrast to BH4-Bcl-2, BH4-Bcl-2 K/D did not inhibit IICR in intact cells, whereas in contrast to BH4-Bcl-Xl, BH4-Bcl-Xl D/K was able to significantly reduce IICR. Similar results were obtained using the physiological agonist ATP (1 mM; Figure 5g ), whereas none of the BH4-domain peptides did alter the amount of TG (2.5 mM)-releasable Ca 2 þ from the ER (Figure 5h ).
The importance of this critical residue was underpinned by SPR experiments using immobilized biotin-BH4-Bcl-2 K/D and biotin-BH4-Bcl-Xl D/K. Consistent with the functional data, BH4-Bcl-2 K/D largely lost its ability to interact with Taken together, these data indicate that one single residue difference between BH4-Bcl-2 and BH4-Bcl-Xl can explain their differential action on IP 3 Rs.
BH4-Bcl-2
and BH4-Bcl-Xl differentially affect apoptosis. Next, we assessed whether BH4-Bcl-2 and BH4-Bcl-Xl displayed a difference in protection against apoptotic cell death in C6 glioma cells triggered by loading the cells with cytochrome c (CytC; 10 mM, 25 min) or by incubation with staurosporine (STS; 2 mM, 6 h). The apoptotic index (AI) was determined and expressed relative to the condition in which apoptosis was triggered in the absence of BH4 peptides (vehicle), which was set to 100%.
We first examined whether CytC interaction with the IP 3 R contributed to CytC-induced apoptosis in the C6 cell model. The CytC-IP 3 R interaction is part of a positive feedback loop that enhances cell death by promoting ER Ca 2 þ release through IP 3 R channels. 36, 37 We examined CytC-induced cell death in the absence and presence of a peptide matching the CytC-binding site on IP 3 Rs (IP3RCYT; 50 mM). Cells loaded with IP3RCYT displayed a decrease of B50-60% in CytCinduced cell death ( Figure 6a ). These results indicate that part of the CytC-induced cell death was because of CytC binding to the IP 3 Rs. We tested the different BH4-domain peptides (20 mM) in this cell system and found that both BH4-Bcl-2 and BH4-Bcl-Xl protected against CytC-induced cell death. However, BH4-Bcl-2 was significantly more potent in protecting than BH4-Bcl-Xl (Figure 6b ). The BH4-Bcl-2SCR control did not protect at all. Importantly, changing Lys17 into Asp in BH4-Bcl-2 (BH4-Bcl-2 K/D) reduced the level of protection, thereby resembling BH4-Bcl-Xl. In contrast, changing Asp11 into Lys in BH4-Bcl-Xl (BH4-Bcl-Xl D/K) increased cell survival, thereby resembling BH4-Bcl-2.
To assess whether the difference in potency between BH4-Bcl-2 and BH4-Bcl-Xl is because of their differential action on the IP 3 R, the BH4-domain peptides were loaded together with IDP competing with the IP 3 R for binding of Bcl-2. IDP completely abolished the protective action of BH4-Bcl-2, but not that of BH4-Bcl-Xl (Figure 6c ).
We also used STS, which acts upstream of the mitochondria and CytC release and initiates apoptosis via ER Ca 2 þ -release-dependent mechanisms. 38, 39 STS induced apoptosis with a minor fraction of these cells displaying secondary necrosis ( Figure 6d ). Primary necrosis was not observed, as all propidium iodide (PI)-positive cells were also characterized by activated caspases (cysteine-dependent . Area under the curve of different control cells was determined and set at 100%. (h) Similar experiment as in (e and f), except that cells were pretreated for 1 min with EGTA (1 mM) and exposed to thapsigargin (TG, 2.5 mM). Area under the curve for control was determined and set at 100%. Statistically significant differences were considered at Po0.05 (single symbols), Po0.01 (double symbols) and Po0.001 (triple symbols). (i) Quantitative analysis of data obtained from three independent SPR experiments, in which the binding of different concentrations of GST-Dom3 to immobilized biotin-BH4-Bcl-2 was compared with its binding to immobilized biotin-BH4-Bcl-2 K/D. The maximal signal (resonance units) during the association phase was used in this analysis. (j) Quantitative analysis of data obtained from SPR experiments, in which the binding of GST-Dom3 to biotin-BH4-Bcl-Xl was compared with its binding to biotin-BH4-Bcl-Xl D/K. The maximal signal (resonance units) during the association phase was used in this analysis Different BH4-motif properties of Bcl-2 and Bcl-Xl G Monaco et al aspartate-specific proteases). Results with STS were similar to those obtained with CytC loading (Figure 6e ). Both BH4-Bcl-2 and BH4-Bcl-Xl, but not BH4-Bcl-2SCR, protected against STSinduced cell death. However, BH4-Bcl-2 was significantly more potent than BH4-Bcl-Xl. BH4-Bcl-2-mediated protection against STS was completely suppressed by IDP, whereas the effect of BH4-Bcl-Xl was independent of IDP.
As an additional control, we used first procaspase activating compound (PAC-1; 150 mM, 6 h), a direct procaspase-3 activating compound downstream of CytC. 40 These conditions caused apoptosis in B15% of the cell population. We found that BH4-Bcl-2 and BH4-Bcl-Xl did not protect against PAC-1-induced cell death, confirming that the target of these peptides is indeed upstream of caspase-3 ( Figure 6f ). Collectively, these data indicate that the BH4 domains of Bcl-2 and Bcl-Xl both protect against apoptosis by acting on different targets upstream of caspase activation. Although the protective effect of BH4-Bcl-2 was stronger and largely dependent on its interaction with a specific binding site on the IP 3 R, the protective effect of BH4-Bcl-Xl is independent of binding to the IP 3 R. Nevertheless, in these paradigms Different BH4-motif properties of Bcl-2 and Bcl-Xl G Monaco et al BH4-Bcl-Xl likely acts on a target that functions downstream of the IP 3 R-signaling cascade.
Full-length Bcl-2 K/D is less efficient in binding IP 3 Rs, inhibiting IP 3 R activity and protecting against Ca 2 þ -dependent apoptosis. Finally, we tested whether the critical Lys17 identified in BH4-Bcl-2 plays a crucial role in the IP 3 R-inhibitory action of full-length Bcl-2. Therefore, we mutated Lys17 into Asp in full-length 3xFLAG-Bcl-2, creating 3xFLAG-Bcl-2 K/D.
First, we compared the GST-Dom3-binding properties of 3xFLAG-Bcl-2 and 3xFLAG-Bcl-2 K/D by expressing these proteins in COS-1 cells and using GST pull-down assays (Figure 7a ). We found that the binding of 3xFLAG-Bcl-2 K/D to GST-Dom3 was severely compromised compared with wildtype 3xFLAG-Bcl-2 ( Figure 7b) .
Next, we examined the effect of 3xFLAG-Bcl-2 and 3xFLAG-Bcl (Figure 7f ). 3xFLAG-Bcl-2 was much more potent in inhibiting IP 3 R-mediated Ca 2 þ signals than 3xFLAG-Bcl-2 K/D (Figure 7f ). In addition, there was no difference for TG-induced Ca 2+ signals (Figure 7g ). Finally, we examined the effect of 3xFLAG-Bcl-2 and 3xFLAG-Bcl-2 K/D overexpression on the protection against STS-induced apoptosis. We used the cleavage of poly-(ADP-ribose)-polymerase (PARP), a downstream target of activated caspase-3, to monitor STS-induced apoptosis in transfected COS-1 cells (Figure 7h ). Compared with control cells, 3xFLAG-Bcl-2 significantly reduced PARP cleavage upon STS treatment. 3xFLAG-Bcl-2 K/D was much less potent than 3xFLAG-Bcl-2 in preventing STS-induced PARP cleavage (Figure 7i) .
We confirmed these findings in WEHI7.2 cells, which contain very low Bcl-2 levels. We created stable WEHI7.2 cell lines expressing either Bcl-2 or Bcl-2 K/D. First, western blotting analysis revealed that both stable cell lines displayed similar levels of Bcl-2 and Bcl-2 K/D (Figure 8a) . Next, we monitored apoptosis by western blotting analysis with PARP antibodies (Figure 8b) , annexin V-fluorescein isothiocyanate (FITC)/PI fluorescence-activated cell sorting (FACS) analysis (Figures 8c and d) and caspase-3-activity assay (Figure 8e) . In all assays, Bcl-2 overexpression protected WEHI7.2 cells against STS-induced apoptosis, whereas Bcl-2 K/D was less effective than wild-type Bcl-2. These data correlate well with the IP 3 R-binding and Ca 2 þ -signaling results obtained in COS-1 cells. Hence, Lys17 seems an important residue in the BH4 domain of full-length Bcl-2 for mediating Bcl-2-dependent inhibition of IP 3 R-mediated Ca 2 þ signals and protection against STS-induced cell death.
Discussion
The major findings of this study are that (1) BH4-Bcl-2 and BH4-Bcl-Xl, although very similar in primary sequence and secondary structure, 29, 34, 35 act differentially on IP 3 Rs, IICR and Ca 2 þ -dependent apoptosis; (2) one critical residue that has an opposite charge in BH4-Bcl-2 versus BH4-Bcl-Xl is responsible for their distinct biological properties; and (3) mutating this residue in the BH4 domain of full-length Bcl-2 decreases its ability to bind and inhibit IP 3 Rs and to protect against apoptotic stimuli. We pinpointed one residue critical for inhibiting IP 3 Rs in the sequence of BH4-Bcl-2 (Lys17) that was not conserved in BH4-Bcl-Xl (Asp11). This residue is of key importance for the specific action of BH4-Bcl-2 on the IP 3 R. Changing Asp11 in BH4-Bcl-Xl into a Lys induced IP 3 R binding and inhibition, leading to a BH4-Bcl-2-like function.
Bcl-2 and Bcl-Xl both act at the mitochondrial and the ER membranes, where they regulate ER Ca 2 þ dynamics via interaction with the IP 3 R. [20] [21] [22] [23] 26 Several reports suggested that Bcl-2 predominantly inhibits proapoptotic Ca 2 þ transients, whereas Bcl-Xl predominantly stimulates $ The combination of BH4-Bcl-2 and BH4-Bcl-Xl is significantly different from BH4-Bcl-Xl, but not from BH4-Bcl-2. These results indicate no additive effect by combining BH4-Bcl-2 with BH4-Bcl-Xl. (h) Effect of BH4-Bcl-2 and BH4-Bcl-Xl on CytC-induced apoptosis in the presence of IP3RCYT peptide. *All conditions significantly reduced CytC-induced apoptosis. However, the protective effects of both BH4-Bcl-2 and BH4-Bcl-Xl were ablated in the presence of IP3RCYT peptide (50 mM) and thus did not significantly differ from the vehicle-treated condition Different BH4-motif properties of Bcl-2 and Bcl-Xl G Monaco et al IP 3 R-mediated prosurvival Ca 2 þ oscillations. [21] [22] [23] 26, 28 Nevertheless, other reports showed that Bcl-2 too may enhance IP 3 R activity 20, 25 and/or stimulate Ca 2 þ oscillations. 21, 41 Hence, until now, it was not clear whether Bcl-2 and Bcl-Xl displayed distinct functional properties toward regulating IP 3 Rs and thus Ca 2 þ -regulated apoptosis or whether they were similar in their action. As we recently showed that BH4-Bcl-2 was sufficient to protect against IP 3 R-mediated apoptosis, we now made a direct comparison of the BH4-domain properties of Bcl-2 and Bcl-Xl by using synthetic peptides. Our study reveals a specific cellular function for the BH4 domain of Bcl-2 as a potent inhibitor of IICR and Ca 2 þ -dependent apoptosis, which is not shared by the BH4 domain of Bcl-Xl, although both motifs are very similar in sequence and structure. Our data indicate that this is because of a critical charge difference in one of the surface-accessible amino-acid residues. As a result, BH4-Bcl-Xl did not inhibit Ca 2 þ flux through the IP 3 R. Nevertheless, BH4-Bcl-Xl protected against cell death.
Different BH4-motif properties of Bcl-2 and Bcl-Xl G Monaco et al However, this effect was significantly smaller than for BH4-Bcl-2 and was not due to inhibition of IICR. This was concluded from the observation that IDP counteracting the effect of BH4-Bcl-2 did not interfere with the protective function of BH4-Bcl-Xl. Finally, using exogenous expression in COS-1 and WEHI7.2 cells, we demonstrated that the role of Lys17 is important for the action of full-length Bcl-2 on the IP 3 R, as full-length Bcl-2 K/D was much less efficient in binding and inhibiting IP 3 Rs as well as in protecting against apoptotic stimuli. We observed a weak binding of full-length Bcl-2 K/D (i.e. B20% of the binding of wild-type Bcl-2) to the IP 3 R fragment, which indicates that residues other than Lys17 may contribute to the binding of full-length Bcl-2 to the IP 3 R. This remaining binding of Bcl-2 K/D to IP 3 R may be responsible for the weak inhibitory property of this protein on IP 3 R-mediated Ca 2 þ signaling and its protective effects against STS-induced apoptosis. However, the latter may also be related to the antiapoptotic actions of Bcl-2 K/D through its hydrophobic cleft and may therefore suggest that its ability to scaffold proapoptotic BH3-domain proteins is unaffected by this mutation in the BH4 domain.
Clearly, whereas Bcl-2 exclusively interacts with the central domain of the IP 3 R, 28 Bcl-Xl seems to interact with the C-terminal tail of the IP 3 R. 23 The latter domain has been proposed to contain two putative BH3-like domains and may therefore interact with the hydrophobic cleft of Bcl-Xl. 24 Besides the differential interaction with the IP 3 R, Bcl-2 and Bcl-Xl could also differ with respect to other previously identified targets of the BH4 domain of Bcl-2-family members, as calcineurin, VDAC, RAF-1 (v-raf-1 murine leukemia viral oncogene homolog 1), RAS (RAt Sarcoma), CED (cell death abnormal)-4, paxillin and NF-kB (nuclear factor kappa-lightchain enhancer of activated B cells), all of which may play a role in apoptosis. 30 A side-by-side comparison between Bcl-2 and Bcl-Xl will be required to examine whether there is a distinct or preferential action of either domain on these targets and whether the critical sequence difference between BH4-Bcl-2 and BH4-Bcl-Xl revealed in this study affects their activity or selectivity. Furthermore, considering the preferential targeting of Bcl-Xl to the mitochondrial outer membrane, 42 we speculate that the protective action of BH4-Bcl-Xl may be mediated by modulating mitochondrial targets. 43 Although BH4-Bcl-2 and BH4-Bcl-Xl appear to have distinct targets, these targets likely do not function in completely independent pathways. Indeed, a combination of BH4-Bcl-2 and BH-Bcl-Xl did not provoke an additive protective effect and IP3RCYT abolished the protective effect of both BH4-Bcl-2 and BH4-Bcl-Xl against CytC-induced apoptosis. Thus, Bcl-Xl may act through its BH4 domain on a target downstream of the IP 3 R, whereas other targets independently of the IP 3 R/Ca 2 þ -signaling cascade cannot be excluded.
Our study may have important therapeutic consequences for cancers dependent on high levels of Bcl-2, like chronic lymphocytic leukemia. 44, 45 It may be possible to target the BH4 domain of Bcl-2 in these malignancies, while preserving essential biological functions of Bcl-Xl in other cells.
To conclude, our study is the first to reveal a difference in the cellular activity of the BH4 domain of Bcl-2 and Bcl-Xl toward IP 3 R regulation because of a single residue difference between both domains.
Materials and Methods
Peptides. All synthetic peptides were obtained from Thermo Electron (Osterode, Germany). Biotinylated peptides were obtained from Lifetein (South Pleinfield, NJ, USA). Table 1 Western-blot analysis using anti-PARP antibodies for monitoring PARP cleavage upon STS treatment (1 mM for 6 h) in 3xFLAG-vector, 3xFLAG-Bcl-2 and 3xFLAG-Bcl-2 K/D-expressing COS-1 cells. GAPDH was used as a loading control. (i) Quantification of the immunoreactive bands of the ratio of the cleaved over the full-length PARP in the different transfected COS-1 cell populations from three independent experiments. The ratio of cleaved over full-length PARP obtained for control cells were set at 100% and the other ratios were normalized to this value. Both 3xFLAG-Bcl-2 and 3xFLAG-Bcl-2 K/D significantly (*) prevent STS-induced apoptosis compared with the empty-vector control, but 3xFLAG-Bcl-2 K/D is significantly ($) less potent than 3xFLAG-Bcl-2. Statistically significant differences are indicated as in Figure 5 . We wish to remark that the results obtained with 3xFLAG-Bcl-2 K/D were borderline significantly (*!) different from the empty-vector control (P ¼ 0.051)
Cell culture and transfections. MEF cells were cultured at 371C in a 9% CO 2 incubator in DMEM/Ham's F12 medium (1 : 1; Invitrogen, Merelbeke, Belgium) supplemented with 10% fetal calf serum (Sigma-Aldrich), 3.8 mM L-glutamine (Glutamax, Invitrogen), 85 IU/ml penicillin and 85 mg/ml streptomycin (Invitrogen). C6 glioma cells were cultured in DMEM/Ham's F12 medium (1 : 1), containing 10% fetal calf serum, 100 IU/ml penicillin, 100 mg/ml streptomycin, 2.5 mg/ml fungizone and 2 mM L-glutamine at 371C, 5% CO 2 . COS-1 cells were seeded at a density of 15 000 cells/cm 2 and cultured in DMEM supplemented with 10% fetal bovine serum (Sigma-Aldrich) at 371C, 10% CO 2 . At 2 days after plating, COS-1 cells were transiently transfected with the empty p3xFLAG-Myc-CMV-24 vector (SigmaAldrich) or containing the cDNA of Bcl-2 or of the Bcl-2 K/D mutant. The transfection procedure was performed using JetPRIME transfection reagent (Polyplus Transfections, New York, NY, USA) and following the manufacturer's recommendations. For Ca 2 þ -imaging experiments, COS-1 cells were also co-transfected with a pcDNA 3.1-mCherry vector (Invitrogen) using a DNA ratio of 1 : 2 between pcDNA 3.1-mCherry and p3xFLAG-Myc-CMV-24 vectors. (e) Fluorimetric analysis from three independent experiments of the caspase-3 activity in untreated and STS-treated control, Bcl-2-overexpressing and Bcl-2 K/D overexpressing WEHI7.2 cells using a plate-reader assay. The difference in relative fluorescence units between STS-treated and untreated cells was calculated and plotted. In all these experiments, both Bcl-2 and Bcl-2 K/D significantly (*) protected against STS-induced apoptosis, but Bcl-2 K/D was significantly ($) less potent than Bcl-2. Statistically significant differences are indicated as in Figure 5 Different BH4-motif properties of Bcl-2 and Bcl-Xl G Monaco et al WEHI7.2 murine cells were grown as described previously 28 and nucleofected with either pSFFV-Neo, pSFFV-Neo-Bcl-2 or pSFFV-Neo-Bcl-2 K/D vectors, using the Amaxa nucleofector and the dedicated Mouse T cell Nucleofector Kit according to the manufacturer's instructions (Amaxa-Lonza AG, Basel, Switzerland). Subsequently, resistant cells were stably selected with 1 mg/ml G418 (Invitrogen) as described in Chen et al., 21 but no clonal expansion was performed.
Western-blot analysis and antibodies. COS-1 and WEHI7.2 cells were lyzed in a buffer containing 25 mM Hepes, pH 7.5, 1% Triton X-100, 10% glycerol, 0.3 M NaCl, 1.5 mM MgCl 2 , 1 mM DTT, 2 mM EDTA, 2 mM EGTA and protease inhibitor cocktail tablets (Roche, Basel, Switzerland). The protein concentration of samples was determined by Bradford assay (Sigma-Aldrich) using bovine serum albumin (BSA) as standard. Proteins (10-20 mg) were separated by NuPAGE 4-12% Bis/Tris SDS-polyacrylamide gels using MES/SDS-running buffer (Invitrogen) and transferred onto a polyvinylidene fluoride (PVDF) membrane. After blocking with TBS containing 0.1% Tween and 5% non-fat dry milk powder, the membrane was incubated with the primary antibody overnight. Next, membranes were incubated for 1 h with a secondary horseradish peroxidase (HRP)-conjugated antibody (dilution 1 : 2000 in 0.1% Tween/TBS). Protein detection was performed with Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific; p/a Perbio Science BVBA, Erembodegem, Belgium). Bands quantification was done with ImageJ software (rsbweb.nih.gov/ij/). Primary antibodies used in this study are: mouse monoclonal ANTI-FLAG M2-Peroxidase (HRP) (Sigma-Aldrich), rabbit polyclonal anti-PARP-1 (Alexis-Enzo Life Sciences, Farmingdale, NY, USA), mouse monoclonal Anti-GAPDH clone GAPDH-71.1 (Sigma-Aldrich) and mouse monoclonal anti-Bcl-2 (C2) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Unidirectional 45
Ca 2 þ -flux assay. The 12-well clusters containing MEF cells were fixed on a thermostated plate at 301C on a mechanical shaker. The culture medium was aspirated, and the cells were permeabilized by incubating them for 10 min in a solution containing 120 mM KCl, 30 mM imidazole-HCl (pH 6.8), 2 mM MgCl 2 , 1 mM ATP, 1 mM EGTA and 20 mg/ml saponin. The non-mitochondrial Ca 2 þ stores were then loaded for 45 min in 120 mM KCl, 30 mM imidazole-HCl (pH 6.8), 5 mM MgCl 2 , 5 mM ATP, 0.44 mM EGTA, 10 mM NaN 3 to prevent mitochondrial Ca 2 þ uptake, and 150 nM free 45 Ca 2 þ (28 mCi/ml). After reaching steady-state loading, cells were washed twice with 500 ml of efflux medium (120 mM KCl, 30 mM imidazole-HCl (pH 6.8), 1 mM EGTA) supplemented with 4 mM thapsigargin (Enzo Life Sciences, Farmingdale, NY, USA) to block SERCA (sarcoplasmic-endoplasmic reticulum Ca 2 þ adenosine triphosphatase) Ca 2 þ -uptake activity. Then, efflux medium was added and replaced every 2 min. IP 3 (3 mM) was added for 2 min after 10 min of efflux. At the end of the experiment, all 45 
Ca
2 þ remaining in the stores were released by incubation with 1 ml of a 2% (w/v) SDS solution for 30 min. Ca 2 þ release was plotted as fractional loss (%/2 min) as a function of time as previously described. 46 The fractional loss represents the amount of Ca 2 þ leaving the store in a 2-min time period divided by the total store Ca 2 þ content at that time point. The effect of these BH4-domain peptides on IICR was tested by preincubating the peptides 4 min before exposing the stores to IP 3 .
Electroporation loading. In situ electroporation of monolayer cell cultures was performed as described before, 32 according to a procedure that was optimized for cell-death studies. 33 25 mM Hepes, pH 7.4) and subsequently three times with a low-conductivity electroporation buffer (4.02 mM KH 2 PO 4 , 10.8 mM K 2 HPO 4 , 1.0 mM MgCl 2 , 300 mM sorbitol, 2.0 mM Hepes, pH 7.4). They were placed 400 mm underneath a two-wire Pt-Ir electrode on the microscopic stage and electroporated in the presence of a tiny amount of electroporation solution (10 ml). Electroporation was done with 50 kHz bipolar pulses applied as trains of 10 pulses of 2 ms duration each and repeated 15 times. The field strength was 100 V peak-to-peak applied over a 500 mm electrode separation distance. After electroporation, cells were thoroughly washed with HBSS-Hepes.
Fluo-3 Ca
2 þ imaging. C6 cells were seeded on 18 mm diameter glass coverslips and ester-loaded for 25 min with 5 mM Fluo-3-AM (Invitrogen) in HBSSHepes supplemented with 1 mM of probenecid (Sigma-Aldrich) and 0.01% pluronic F-127 (Invitrogen) at 371C, followed by de-esterification over 15 min. Subsequently, cells were loaded with 100 mM Dextran Texas Red (DTR; Invitrogen) and 20 mM Bcl-2 peptides using the in situ electroporation technique as described above. For UV flash-photolysis experiments, 50 mM caged IP 3 (Invitrogen) was also included in the loading solution. Imaging was carried out using an inverted fluorescence microscope equipped with a Â 40 oil-immersion objective and an intensified CCD camera (Extended Isis camera, Photonic Science, East Sussex, UK).
In the case of stimulation by ATP, cells were superfused for 1 min with HBSSHepes followed by 8 min with 1 mM of ATP (Sigma-Aldrich) in HBSS-Hepes, whereas for TG experiments, cells were superfused for 1 min with Ca 2 þ -free HBSS-Hepes containing 1 mM EGTA followed by 7 min with 2.5 mM TG (Invitrogen) in the same buffer. For IP 3 -photoliberation experiments, cells were, after 10 s, spot illuminated with 1-kHz pulsed UV light (349 nm UV laser Explorer, Spectra-Physics, Oxfordshire, UK) during 20 ms (20 pulses of 90 mJ energy measured at the entrance of the microscope epifluorescence tube). The UV flash was applied at five different places along the electroporated area per dish. Images (1/s) were generated with software written in Microsoft Visual C þ þ 6.0 (http://msdn.microsoft.com/en-us/ aa336402). Fluorescence-intensity changes in different cells (at least 20) were analyzed with custom-developed FluoFrames software (generated by L Leybaert Lab.). For UV flash photolysis experiments, fluorescence-intensity changes in all cells in a predefined 3950 mm 2 region were analyzed. Ca 2 þ -concentration, (Ca 2 þ ), changes were quantified as the area under the curve (AUC) of the separate Ca 
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Peptide sequence 4 ; Invitrogen) using Slide-A-Lyzer with a cutoff of 3 kDa (Thermo Fisher Scientific, Pittsburg, PA, USA). After dialysis, the concentration of the purified GST-fusion proteins was determined using BCA Protein Assay Reagent (Thermo Fisher Scientific), and the quality and integrity were examined by SDS-PAGE and GelCode blue stain reagent (Thermo Fisher Scientific) before GST pull-downs or SPR analysis.
GST pull-downs. Equal amounts (30 mg) of the intact full-length GST-fusion proteins or parental GST (control) were incubated in Interaction Buffer (50 mM Tris-HCl, 300 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.5% BSA and protease inhibitor cocktail, pH 7.0) with 30 mg of different BH4 domains (BH4-Bcl-2, BH4-Bcl-Xl or a non-binding mutant (BH4-Bcl-2BIND)) and immobilized on glutathione-Sepharose 4B beads (GE Healthcare Europe GmbH, Munich, Germany) via rotation in a head-over-head rotator for 2 h at 41C. The beads were washed four times with modified Interaction Buffer (150 mM NaCl instead of 300 mM NaCl, without BSA) and complexed GST-fusion proteins were eluted by incubating the beads with 40 ml LDS (Invitrogen) for 3 min at 951C and collected after centrifuging at 500 Â g for 5 min. Eluates (10 ml) were subjected to western-blot analysis and the total protein content was visualized by GelCode blue staining of the gel.
For the pull-downs with full-length Bcl-2 proteins, 200 mg of cleared lysate from COS-1 cells transiently transfected with the 3xFLAG-Bcl-2 vector, 3xFLAG-Bcl-2-K/ D or the empty vector were incubated with GST-tagged proteins using the same protocol as above. Eluates (10 ml) were subjected to western-blot and incubated with anti-FLAG HRP-conjugated antibody, diluted 1 : 4000 in 0.1% Tween/TBS. SPR measurements. SPR experiments were performed as described before. 47 The binding of GST-Dom3 and parental GST (control) to the wild-type or mutated BH4 domain of Bcl-2 or Bcl-Xl was analyzed by SPR at 251C using a Biacore 2000 instrument (Uppsala, Sweden). Equal amounts (200 ng or 58.2 pmol) of 480% pure biotinylated BH4 peptides were immobilized on four different flow cells of a streptavidin-coated sensor chip (BR-1000-32; Biacore, Uppsala, Sweden) using PBS supplemented with 0.005% P20 (Polysorbate-20) at pH 7.0. At least three independent sensor chips were used for the quantitative analysis.
Measurements with GST-fusion proteins as analyte were performed in PBS at a flow rate of 30 ml/min. Different concentrations of the analyte (injection volume 120 ml) were used in a random order to assess binding, expressed in terms of resonance units (RU). Bound peptide was removed by injection of 5 ml regeneration buffer (25 mM NaOH, 0.002% SDS) at 10 ml/min. Background signals were obtained from the reference flow cell, containing the BH4-scrambled peptide, and were subtracted to generate response curves using Biaevaluation 3.0 software (Biacore, http://www.biacore.com). In the analysis, only the association phase of the binding curve was taken into account. Data from two to three different sensorgrams for each condition were fitted by nonlinear regression analysis to a Hill-Langmuir binding isotherm using Origin 7.0 (OriginLab Corporation, Northampton, MA, USA) software.
Fura-2 Ca 2 þ imaging. At 2 days after co-transfection (mCherry þ 3xFlag construct), COS-1 cells were loaded with Fura-2-AM (5 mM; Biotium, Inc., Hayward, CA, USA) in modified Krebs buffer (135 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl 2 , 11.6 mM Hepes, pH 7.3, 11.5 mM glucose and 1.5 mM Ca 2 þ ) for 30 min, followed by de-esterification for 30 min. To buffer all free extracellular Ca 2 þ , 5 mM BAPTA (Invitrogen) was added before each measurement. ATP (1 mM) or TG (5 mM)-induced [Ca 2 þ ] rises were measured ratiometrically (excitation at 340 nm/380 nm, emission detection at 510 nm) using Zeiss Axio Observer Z1 Inverted Microscope equipped with a Â 20 air objective and an high-speed digital camera (Axiocam Hsm, Zeiss, Jena, Germany). Intracellular cytoplasmic Ca 2 þ concentrations ([Ca 2 þ ] cyt ) were calculated from the equation: [Ca 2 þ ] cyt (nM) ¼ K d Â Q Â (R-R min )/(R max -R), where K d is the dissociation constant of Fura-2 for Ca 2 þ at room temperature (220 nM), Q is the fluorescence ratio of the emission intensity excited by 380 nm in the absence of Ca 2 þ to that in the presence of saturating Ca 2 þ , R is the fluorescence ratio, R min and R max are the minimal and maximal fluorescence ratios, respectively. The R min was measured by perfusion with 50 mM EGTA in Ca 2 þ -free Krebs solution and R max was obtained by perfusion with 5 mM ionomycin and 250 mM CaCl 2 . Only mCherry fluorescent (excitation 546 nm, emission 610 nm) and Fura-2 loaded cells were considered for data analysis. Per experiment, 10-15 cells were analyzed for a total of B80 cells per transfection condition on 3 different experimental days. Traces were normalized to baseline levels with Excel software (Microsoft Office) and for each experiment the average peak value (D[Ca 2 þ ] cyt ) was determined.
Apoptosis induction. For CytC-induced-apoptosis experiments, C6 cells were loaded by in situ electroporation in the presence of 100 mM DTR to identify the loaded zone, 20 mM of Bcl-2 peptides or 50 mM IP3RCYT peptide and 10 mM of CytC (Sigma). After electroporation, cells were kept in 200 ml culture medium for 25 min. For STS-and PAC-1-induced apoptosis experiments, cells were electroporated in the presence of 100 mM DTR and 20 mM Bcl-2 peptides. After electroporation, cells were kept in 200 ml culture medium containing 2 mM STS (Sigma-Aldrich) or 150 mM PAC-1 (Tocris Bioscience, Ellisville, MO, USA) for 6 h. For STS-induced apoptosis, COS-1 cells transiently transfected with 3xFLAG-vectors and WEHI7.2 cells, and stably transfected with the various pSFFV-Neo vectors, were treated for 6 h with 1 mM STS (Sigma-Aldrich).
Detection of apoptosis by fluorescence microscopy. Glioma cells were stained first with 10 mM of the CaspACE FITC-VAD-FMK 'In situ Marker' (Promega Benelux, Leiden, The Netherlands) in HBSS-Hepes for 40 min at 371C. After fixing the cells with 4% paraformaldehyde (PFA) for 25 min at room temperature, nuclei were additionally stained for 5 min with 1 mg/ml DAPI (Sigma) in PBS supplemented with Ca 2 þ and Mg 2 þ (PBSD þ ). Cells were mounted with Vectashield fluorescent mounting medium (VWR International, Leuven, Belgium) on glass slides.
Five images (in each culture) were taken in the electroporated area using a Nikon TE300 epifluorescence microscope equipped with a Â 10 objective (Plan APO, NA 0.45; Nikon) and a Nikon DS-5M camera (Nikon, Brussels, Belgium). The number of caspase-positive cells and DNA-fragmented nuclei were counted in each image and expressed relative to the number of nuclei present and stated as the AI. Small groups of apoptotic bodies were counted as remnants of a single apoptotic cell. Analyses were carried out blinded, making use of custom-developed counting software. For the STS-and PAC-1-treated cultures, five additional images were taken outside the electroporated area. The AI in the electroporated area was expressed relative to the AI outside the area.
